Breaking News Instant updates and real-time market news.

MYL

Mylan

$30.44

-0.28 (-0.91%)

, BIP

Brookfield Infrastructure

$44.78

0.135 (0.30%)

10:29
08/22/17
08/22
10:29
08/22/17
10:29

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mylan (MYL) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing the cut in 2017 guidance. He said Mylan may also have difficulty improving operations in the near-term due to unfavorable EpiPen regulatory developments, pricing pressures, and increased competition. 2. Brookfield (BIP) downgraded to Neutral from Outperform at Credit Suisse, with analyst Andrew Kuske saying he is exiting his long "tactical trade" given recent outperformance. 3. Global Medical REIT (GMRE) downgraded to Neutral from Buy at DA Davidson with analyst Barry Oxford saying that the stock "could be range bound for a period of time" following the departures of the REIT's CEO and CFO and due to "potential concerns regarding the dividend and acquisitions." 4. NxStage Medical (NXTM) downgraded to Market Perform from Outperform at Leerink, as analyst Danielle Antalffy said it is unlikely another bidder will top Fresenius Medical's (FMS) $30 per share offer for the company. 5. Hikma (HKMPY) downgraded to Neutral from Buy at Goldman Sachs, with analyst Yulia Gerasimova citing Roxane integration issues, delayed generic Advair approval, ongoing U.S. generics pricing erosion, and multiple guidance downgrades from the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MYL

Mylan

$30.44

-0.28 (-0.91%)

BIP

Brookfield Infrastructure

$44.78

0.135 (0.30%)

GMRE

Global Medical REIT

$8.38

-0.6 (-6.68%)

NXTM

NxStage Medical

$29.11

-0.14 (-0.48%)

FMS

Fresenius Medical

$46.69

0.37 (0.80%)

HKMPY

Hikma

  • 23

    Aug

  • 03

    Sep

  • 06

    Sep

  • 08

    Sep

  • 15

    Sep

  • 09

    Oct

MYL Mylan
$30.44

-0.28 (-0.91%)

08/22/17
ARGS
08/22/17
DOWNGRADE
ARGS
Hold
Mylan downgraded to Hold from Buy at Argus
Argus analyst Jasper Hellweg downgraded Mylan to Hold due to the cut in 2017 guidance and said it may also have difficulty improving operations in the near-term due to unfavorable EpiPen regulatory developments, pricing pressures, and increased competition.
08/16/17
08/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: Home Depot (HD) upgraded to Outperform from Market Perform at Raymond James with analyst Budd Bugatch saying the company continues to execute at a "world-class level." 2. Mylan (MYL) upgraded to Buy from Neutral at Citi with analyst Liav Abraham saying the company is best positioned to execute in a challenging operating environment for generics. 3. Biogen (BIIB) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Terence Flynn saying he continues to see optionality Aducanumab, its lead pipeline Alzheimer's drug. 4. Zions Bancorp (ZION) upgraded to Buy from Neutral at BofA/Merrill with analyst Erika Najarian saying she believes investors are discounting two catalysts for earnings upside including benefits from regulatory reform for regionals and continued improvement in expense management. 5. Paychex (PAYX) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Danyal Hussain saying expectations adequately capture downside risks and the valuation premium is the lowest since 2008. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/17
SBSH
08/16/17
DOWNGRADE
Target $19
SBSH
Neutral
Teva downgraded to Neutral from Buy at Citi
Citi analyst Liav Abraham downgraded Teva Pharmaceutical (TEVA) to Neutral and cut her price target for the shares to $19 from $32. The analyst this morning also upgraded Mylan (MYL) to Buy. Teva is "cheap, but not cheap enough," Abraham tells investors in a research note. She needs to see the appointment of a "respected" CEO and formulation of a credible long-term strategy as well as improvement in the credit situation before getting more constructive on Teva shares.
08/16/17
SBSH
08/16/17
UPGRADE
Target $42
SBSH
Buy
Mylan upgraded to Buy from Neutral at Citi
Citi analyst Liav Abraham upgraded Mylan (MYL) to Buy and raised her price target for the shares to $42 from $36. The company is best positioned to execute in a challenging operating environment for generics, Abraham tells investors in a research note. Mylan has a "differentiated and durable" generics product portfolio, "broad pipeline" of complex generics/ biosimilars and a more favorable balance sheet profile relative to peers, the analyst contends. She has Neutral ratings on Teva (TEVA) and Endo (ENDP).
BIP Brookfield Infrastructure
$44.78

0.135 (0.30%)

02/13/17
02/13/17
DOWNGRADE
Target $40

Neutral
Brookfield Infrastructure downgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Andrew Kuske downgraded Brookfield Infrastructure to Neutral from Outperform, with a $40 price target, after media reports stated a Brazilian Federal Justice suspended the sale of the Petrobras's NTS gas pipeline system to the company. The analyst believes there will be legal wrangling ahead that will likely create timing uncertainty.
06/16/17
FBCO
06/16/17
UPGRADE
Target $44
FBCO
Outperform
Brookfield Infrastructure upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Andrew Kuske upgraded Brookfield Infrastructure Partners LP to Outperform and raised his price target shares to $44 from $40. The potential inclusion of Brookfield Infrastructure into the S&P Index is likely to have a "meaningful impact" on demand around the Q3 index revision, Kuske tells investors in a research note. The analyst also believes Brookfield ha a "solid fundamental organic growth story" that is underappreciated.
06/16/17
06/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Teva (TEVA) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler citing reduced near-term risk of a Mylan's (MYL) generic Copaxone approval, potential asset sale announcements, and encouraging May subscription trends. 2. Brookfield Infrastructure (BIP) upgraded to Outperform from Neutral at Credit Suisse with analyst Andrew Kuske saying the potential inclusion of Brookfield Infrastructure into the S&P Index is likely to have a "meaningful impact" on demand around the third quarter index revision. 3. Celgene (CELG) upgraded to Outperform from Market Perform at Leerink with analyst Geoffrey Porges saying he views Celgene's valuation as "discounted." 4. Regency Centers (REG) upgraded to Buy from Hold at Jefferies with analyst George Hoglund saying he believes the recent pullback in the shares creates an attractive entry point. 5. Nanometrics (NANO) upgraded to Buy from Hold at Stifel with analyst Patrick Ho citing valuation, along with his belief that wafer lab equipment spending will be strong next year and that the "elevated spending" level may be sustainable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/22/17
FBCO
08/22/17
DOWNGRADE
FBCO
Neutral
Brookfield downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Andrew Kuske downgraded Brookfield Infrastructure to Neutral saying he is exiting his long "tactical trade" given recent outperformance and maintained a $44 price target on shares.
GMRE Global Medical REIT
$8.38

-0.6 (-6.68%)

03/28/17
COMP
03/28/17
UPGRADE
Target $9.25
COMP
Buy
Global Medical REIT upgraded to Buy from Neutral at Compass Point
Compass Point analyst Steve Shaw upgraded Global Medial REIT to Buy and raised its price target to $9.25 from $9 following the Q4 report and acquisition update saying shares are trading at a discount.
02/23/17
JANY
02/23/17
INITIATION
Target $9
JANY
Buy
Global Medical REIT initiated with a Buy at Janney Capital
Janney Capital analyst Robert Stevenson initiated Global Medical REIT with a Buy and a $9 price target. The analyst is positive on Global's ability to make incremental acquisitions to drive growth, the current 9.5% dividend yield, and exposure to the growth of outpatient healthcare services.
08/22/17
DADA
08/22/17
DOWNGRADE
DADA
Neutral
Global Medical REIT downgraded on stock outlook at DA Davidson
As noted earlier, DA Davidson downgraded Global Medical REIT to Neutral from Buy. Analyst Barry Oxford says that the stock "could be range bound for a period of time" following the departures of the REIT's CEO and CFO and due to "potential concerns regarding the dividend and acquisitions." The analyst says he'is "somewhat concerned" about the REIT's dividend because it will have to "maintain a healthy pace of acquisitions in order to cover their dividend." Target to $10 from $11.
08/21/17
DADA
08/21/17
DOWNGRADE
DADA
Neutral
Global Medical REIT downgraded to Neutral from Buy at DA Davidson
NXTM NxStage Medical
$29.11

-0.14 (-0.48%)

08/22/17
LEER
08/22/17
DOWNGRADE
LEER
Market Perform
NxStage Medical downgraded to Market Perform from Outperform at Leerink
Leerink analyst Danielle Antalffy downgraded NxStage Medical (NXTM) to Market Perform saying it is unlikely another bidder will top Fresenius Medical's (FMS) $30 per share offer for the company.
08/09/17
SPHN
08/09/17
DOWNGRADE
SPHN
Equal Weight
NxStage Medical downgraded to Equal Weight from Overweight at Stephens
NxStage Medical (NXTM) has agreed to be acquired by Fresenius Medical Care (FMS) for $30 per share.
08/07/17
ADAM
08/07/17
DOWNGRADE
ADAM
Hold
NxStage Medical downgraded to Hold from Buy at Canaccord
Canaccord analyst Kyle Rose downgraded NxStage Medical (NXTM) to Hold from Buy after the company agreed to be acquired by Fresenius Medical Care (FMS) for $30 per share.
08/08/17
JEFF
08/08/17
DOWNGRADE
Target $30
JEFF
Hold
NxStage Medical downgraded to Hold from Buy at Jefferies
Jefferies analyst Raj Denhoy downgraded NxStage Medical to Hold citing limited competing bidders and a potentially lengthy close due to antitrust questions. The analyst views Fresenius as the "most logical and likely only buyer" of the company. He lowered his price target for the shares to $30 from $33 following yesterday's deal announcement.
FMS Fresenius Medical
$46.69

0.37 (0.80%)

08/22/17
GABE
08/22/17
NO CHANGE
GABE
Akorn deal still likely to close, says Gabelli
Gabelli says that Akorn's (AKRX) stock fell below $32 last week on worries that Fresenius (FMS) could restructure or break its deal to acquire the company. However, the firm still expects the deal to close, by early next year, as it does not believe that Fresenius' "disappointing" Q2 results or subpoenas related to the pricing of individual drugs would trigger the deal's material adverse event clause. Gabelli keeps a Hold rating on Akorn.
03/21/17
UBSW
03/21/17
DOWNGRADE
UBSW
Neutral
Fresenius SE downgraded to Neutral from Buy at UBS
UBS analyst Ian Douglas-Pennant downgraded Fresenius Medical Care (FMS) two notches, to Sell from Buy, and downgraded parent Fresenius SE (FSNUY) to Neutral from Buy on read through from the downgrade of its subsidiary. He cut his price target on Fresenius SE to EUR74 from EUR75.
03/21/17
UBSW
03/21/17
DOWNGRADE
UBSW
Sell
Fresenius Medical downgraded to Sell from Buy at UBS
UBS analyst Ian Douglas-Pennant downgraded Fresenius Medical Care two notches, to Sell from Buy, as he sees its margins as close to peak and poised to start falling beginning in the second half of 2017 as commentary from the incoming U.S. administration makes him believe value based care in dialysis is likely to be delayed or even cancelled. The analyst cut his price target on Fresenius Medical to EUR68 from EUR100.
04/10/17
RBCM
04/10/17
NO CHANGE
RBCM
Akorn stock already reflects full take-out value, says RBC Capital
RBC Capital analyst Randall Stanicky says that the take-out valuation of drug companies have recently dropped to the historical level of 12 times EBITDA, while Akorn's take-out valuation may be "modestly lower" given the "depressed valuation" of the "generic sector." Consequently, after Bloomberg reported that Fresenius is in talks to acquire Akorn, and Akorn's stock jumped, Stanicky believes that the shares, which have reached 13 times EBITDA in pre=market trading, are fully valued. He does not see another "obvious" buyer for Akorn and keeps a Sector Perform rating on the shares.
HKMPY Hikma

08/21/17
GSCO
08/21/17
DOWNGRADE
GSCO
Neutral
Hikma downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Yulia Gerasimova downgraded Hikma to Neutral from Buy and removed Hikma from Goldman's Pan-Europe Buy List, citing Roxane integration issues, delayed generic Advair approval, ongoing U.S. generics pricing erosion, and multiple guidance downgrades from the company.
08/21/17
JEFF
08/21/17
UPGRADE
JEFF
Hold
Hikma upgraded to Hold from Underperform at Jefferies
Jefferies analyst James Vane-Tempest upgraded Hikma to Hold from Underperform, saying its fundamentals are now skewed more to the upside than the downside. However, he lowered his price target on Hikma to 1,045p from 1,390p.
05/17/17
JEFF
05/17/17
DOWNGRADE
JEFF
Underperform
Hikma downgraded to Underperform from Buy at Jefferies
Price target lowered to 1,450p.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

13:17
09/19/17
09/19
13:17
09/19/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
09/19/17
09/19
13:16
09/19/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Holdings

$76.15

-1.53 (-1.97%)

13:15
09/19/17
09/19
13:15
09/19/17
13:15
Options
HCA Holdings put volume heavy and directionally bearish »

Bearish flow noted in HCA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
09/19/17
09/19
13:15
09/19/17
13:15
General news
Fed Policy Outlook: FOMC began its 2-day meeting »

Fed Policy Outlook: FOMC…

ICPT

Intercept

$95.75

0.87 (0.92%)

13:11
09/19/17
09/19
13:11
09/19/17
13:11
Conference/Events
Intercept management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

WHR

Whirlpool

$170.86

0.02 (0.01%)

13:10
09/19/17
09/19
13:10
09/19/17
13:10
Hot Stocks
Whirlpool ticks lower after August appliance data »

Shares of Whirlpool moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIF

Tiffany

$90.95

1.98 (2.23%)

13:05
09/19/17
09/19
13:05
09/19/17
13:05
Options
Tiffany call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

13:00
09/19/17
09/19
13:00
09/19/17
13:00
General news
FOMC forecast revisions »

FOMC forecast revisions…

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

12:58
09/19/17
09/19
12:58
09/19/17
12:58
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola selloff today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

KR

Kroger

$21.29

-0.1501 (-0.70%)

12:55
09/19/17
09/19
12:55
09/19/17
12:55
Options
Kroger put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

  • 30

    Nov

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

12:51
09/19/17
09/19
12:51
09/19/17
12:51
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

FCAU

Fiat Chrysler

$17.10

0.275 (1.64%)

12:49
09/19/17
09/19
12:49
09/19/17
12:49
Hot Stocks
FCA US recalling 443,712 U.S.-market heavy-duty pickups, medium-duty trucks »

FCA US LLC is voluntarily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$75.16

-0.15 (-0.20%)

12:48
09/19/17
09/19
12:48
09/19/17
12:48
Hot Stocks
Microsoft Azure IP Advantage available in China on October 1 »

Microsoft said on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

AA

Alcoa

$45.77

0.86 (1.91%)

12:45
09/19/17
09/19
12:45
09/19/17
12:45
Options
Alcoa call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$4.15

-0.25 (-5.68%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Conference/Events
Noodles & Company management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ENDP

Endo

$8.34

-0.26 (-3.02%)

, JNJ

Johnson & Johnson

$135.14

-0.24 (-0.18%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Hot Stocks
Schneiderman, coalition of AGs expand multistate probe into opioid crisis »

New York Attorney General…

ENDP

Endo

$8.34

-0.26 (-3.02%)

JNJ

Johnson & Johnson

$135.14

-0.24 (-0.18%)

TEVA

Teva

$17.14

0.15 (0.88%)

AGN

Allergan

$218.48

-3.06 (-1.38%)

ABC

AmerisourceBergen

$80.24

-0.43 (-0.53%)

CAH

Cardinal Health

$66.37

-0.7 (-1.04%)

MCK

McKesson

$150.02

1.6 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 17

    Oct

LXRX

Lexicon

$12.81

0.44 (3.56%)

, IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Hot Stocks
Lexicon announces European Commission approves Xermelo »

Lexicon Pharmaceuticals…

LXRX

Lexicon

$12.81

0.44 (3.56%)

IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

12:35
09/19/17
09/19
12:35
09/19/17
12:35
General news
Today's U.S. reports »

Today's U.S. reports…

LEG

Leggett & Platt

$45.25

-0.635 (-1.38%)

12:34
09/19/17
09/19
12:34
09/19/17
12:34
Conference/Events
Leggett & Platt management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

, VIA

Viacom

$37.45

-0.4 (-1.06%)

12:32
09/19/17
09/19
12:32
09/19/17
12:32
Periodicals
Viacom leak may have compromised digital properties, Gizmodo reports »

A security researcher…

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

VIA

Viacom

$37.45

-0.4 (-1.06%)

VIAB

Viacom

$27.32

-0.35 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ACTG

Acacia Research

12:32
09/19/17
09/19
12:32
09/19/17
12:32
Hot Stocks
Acacia Research shares trade higher amid insider buying »

A number of insiders at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDOT

Green Dot

$48.82

0.79 (1.64%)

12:30
09/19/17
09/19
12:30
09/19/17
12:30
Conference/Events
Green Dot management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$155.77

1.28 (0.83%)

12:30
09/19/17
09/19
12:30
09/19/17
12:30
Options
Adobe attracts a pre-earnings call writer »

Adobe attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 22

    Oct

ENDP

Endo

$8.34

-0.26 (-3.02%)

, JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

12:28
09/19/17
09/19
12:28
09/19/17
12:28
Hot Stocks
Michigan AG says 41 state attorneys general now involved in opioid probe »

Michigan Attorney General…

ENDP

Endo

$8.34

-0.26 (-3.02%)

JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

TEVA

Teva

$17.14

0.15 (0.88%)

AGN

Allergan

$218.49

-3.05 (-1.38%)

ABC

AmerisourceBergen

$80.20

-0.47 (-0.58%)

CAH

Cardinal Health

$66.36

-0.71 (-1.06%)

MCK

McKesson

$149.89

1.47 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 17

    Oct

EFX

Equifax

$94.55

0.17 (0.18%)

12:27
09/19/17
09/19
12:27
09/19/17
12:27
Periodicals
Massachusetts Attorney General files lawsuit against Equifax, Reuters reports »

The State of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.